

## Pfitzner, Laura

---

**From:** Blanch, Belinda on behalf of Adjudication  
**Sent:** Monday, 30 July 2012 1:04 PM  
**To:** Basile, Mark  
**Subject:** FW: disclosure of payments made by the pharmaceutical industry to medical practitioners [SEC=UNCLASSIFIED]

**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

**Security Classification:**  
UNCLASSIFIED

-----Original Message-----

**From:** Anthony Smith  
**Sent:** Monday, 30 July 2012 10:05 AM  
**To:** Adjudication  
**Subject:** disclosure of payments made by the pharmaceutical industry to medical practitioners

I write as a retired clinical academic who for many years conducted joint research with the pharmaceutical industry both here and in the UK.

We always insisted on a formal written contract for the work which was normally reviewed by the University before the work began. Outside that relationship I made it plain that I did not want to serve on advisory boards or to be paid as a speaker at conferences.

I fully support the suggestion that all monetary and in-kind payments made to medical practitioners should be able to be scrutinised on the public record. This has been implemented in the US and the disasters predicted by some sectors of the industry have not eventuated. If this were imposed on the industry here -uniformly- no single industry group could claim to be disadvantaged compared to other companies. Voluntary acceptance of a less rigorous code is very unlikely to succeed.

Sincerely --Anthony Smith

Emeritus Professor Anthony J Smith